Welcome to our dedicated page for Abvc Biopharma SEC filings (Ticker: ABVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ABVC BioPharma, Inc. filings document the regulatory record of a Nevada clinical-stage biopharmaceutical company focused on ophthalmology, CNS, and oncology/hematology programs. The company’s disclosures include Form 8-K reports for financial results and material events, proxy materials for annual shareholder meetings, board elections, and shareholder voting results.
ABVC’s SEC filings also cover governance and capital-structure matters, including unregistered common stock sales under Regulation S, voting-rights proxy arrangements connected to those sales, director and officer compensation arrangements, changes in the company’s independent registered public accounting firm, and formal reporting around shareholder approvals and corporate controls.
ABVC BioPharma filed Prospectus Supplement No. 5 updating its April 5, 2024 prospectus covering 11,714,683 shares of common stock. The supplement appends the company’s Form 10-Q for the quarter ended September 30, 2025.
For Q3 2025, revenue was $795,950 and loss from operations was $1,168,410, leading to a net loss attributable to ABVC of $1,246,513. For the nine months, net loss attributable to ABVC was $4,345,610. Cash and cash equivalents were $192,068 with restricted cash of $661,843 as of September 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern, citing a working capital deficit of $2,434,951 and net cash outflows from operating activities of $1,567,264 for the nine months. Shares outstanding were 24,301,089 as of October 30, 2025; this is a baseline figure, not the amount being offered.
ABVC BioPharma filed Prospectus Supplement No. 5 covering 225,500 shares of common stock and updating its May 22, 2024 prospectus with the company’s Form 10‑Q for the quarter ended September 30, 2025.
For Q3 2025, revenue was $795,950 and net loss attributed to ABVC and subsidiaries was $1,246,513. For the nine months ended September 30, 2025, net loss was $4,564,546. Cash and cash equivalents were $192,068 and restricted cash was $661,843. The filing notes a working capital deficit of $2,434,951 and states there is substantial doubt about the company’s ability to continue as a going concern.
Shares outstanding were 24,301,089 as of October 30, 2025. The company also disclosed restatements affecting 2023 and certain 2024 interim figures, primarily related to stock‑based compensation, convertible note accounting, and noncontrolling interests.
ABVC BioPharma furnished an 8-K to announce its financial results for the third quarter ended September 30, 2025. The company reported these results via a press release attached as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes Exhibit 104, the cover page interactive data file formatted in Inline XBRL. The notice states it is not an offer to sell or solicit purchases of securities.
ABVC BioPharma filed its Q3 2025 Form 10‑Q, reporting revenues of $795,950 for the quarter and $795,950 for the nine months. The company posted a net loss of $1,287,523 for Q3 and $4,564,546 for the nine months, with basic and diluted net loss per share of $0.05 and $0.23, respectively.
Total assets were $21,176,299 as of September 30, 2025, up from $7,539,907 at December 31, 2024, largely reflecting property and equipment, net, of $12,055,642, including land acquisitions in Taiwan. Cash and cash equivalents were $192,068, with restricted cash of $661,843. The company reported a working capital deficit of $2,434,951 and stated that these conditions give rise to substantial doubt about its ability to continue as a going concern.
Operating cash outflow was $1,567,264 for the nine months, offset by $3,488,478 provided by financing activities. The company recognized collaboration revenues from related‑party licensing, including $595,950 from an OncoX agreement and $200,000 from a FEYE amendment during the nine months. ABVC restated prior periods to correct share‑based payment accounting, interest recognition on a convertible note, and non‑controlling interest presentation. Shares outstanding were 24,301,089 as of October 30, 2025.
ABVC BioPharma (ABVC) approved a performance incentive plan for directors, officers, and select employees. The plan will only take effect after the company achieves a $1B market cap for 30 consecutive trading days on or before December 31, 2027, of which there is no guarantee.
If implemented, awards will equal 1% of the company’s common stock outstanding on the implementation date, sourced from the Amended and Restated 2016 Equity Incentive Plan. The plan is capped at $10 million in total awards, with a $1 million cap per recipient. Grants will be tied to defined milestones and require allocation by the Compensation Committee, endorsement by a majority of independent directors, and final approval by the full Board. The structure is intended to align leadership incentives with shareholder value creation.
ABVC BioPharma, Inc. filed an amended current report to update information about its former independent auditor. The company previously disclosed that WWC, P.C., its independent registered public accounting firm, agreed not to renew its engagement as of October 10, 2024.
In this amendment, ABVC explains that it had provided WWC with the earlier report and asked for a letter to the SEC stating whether WWC agreed with the company’s description of the circumstances. ABVC now reports that WWC has refused to provide that letter.
ABVC BioPharma, Inc. filed an amended current report to update information about its former independent auditor. The company previously disclosed that WWC, P.C., its independent registered public accounting firm, agreed not to renew its engagement as of October 10, 2024.
In this amendment, ABVC explains that it had provided WWC with the earlier report and asked for a letter to the SEC stating whether WWC agreed with the company’s description of the circumstances. ABVC now reports that WWC has refused to provide that letter.
ABVC BioPharma, Inc. filed an amended current report to update information about its former independent auditor. The company previously disclosed that WWC, P.C., its independent registered public accounting firm, agreed not to renew its engagement as of October 10, 2024.
In this amendment, ABVC explains that it had provided WWC with the earlier report and asked for a letter to the SEC stating whether WWC agreed with the company’s description of the circumstances. ABVC now reports that WWC has refused to provide that letter.
ABVC BioPharma, Inc. filed an amended current report to update information about its former independent auditor. The company previously disclosed that WWC, P.C., its independent registered public accounting firm, agreed not to renew its engagement as of October 10, 2024.
In this amendment, ABVC explains that it had provided WWC with the earlier report and asked for a letter to the SEC stating whether WWC agreed with the company’s description of the circumstances. ABVC now reports that WWC has refused to provide that letter.
ABVC BioPharma, Inc. reported continued operating losses and a strained liquidity position while advancing multiple clinical programs and licensing arrangements. For the periods shown, the company recorded net losses of $2.33 million and $3.28 million (two comparable periods), with net loss attributable to ABVC of $2.26 million and $3.10 million in the comparable reporting periods. Basic and diluted net loss per share ranged from $(0.08) to $(0.36) depending on period and share count. Current liabilities totaled $6.53 million with a working capital deficit near $(3.76) million. Cash flows show investing uses of $(665,779) and financing proceeds of $2.54 million in the reporting period. Long-term investments and prepayments total several million, and the company discloses substantial related-party loans and short-term borrowings. Clinical pipeline progress includes completed Phase II for ABV-1504 (MDD), ongoing Phase II Part 2 for ABV-1505 (ADHD), planned Phase I for ABV-1601, and initiated Phase II for ABV-1701 Vitargus (medical device). License/milestone schedule includes $1M for IND, $1M for Phase II completion, $3M for Phase III initiation, and $4M for NDA submission.
ABVC BioPharma reported a loss and continuing financing reliance. The filing shows significant operating losses and negative working capital while the company advances multiple clinical and device programs.
For the period presented, net loss attributable to ABVC was $2,257,022 for the quarter and $3,099,097 for the six-month period, with basic and diluted net loss per share of $(0.13) and $(0.19) for the comparable periods. Current liabilities totaled $6,532,514 producing a working capital deficit of $(3,762,113). Long-term investments were $2,837,922 and property and equipment, net was reported at $8,215,366. Cash flow from financing activities provided $2,536,083 while investing used $(665,779). The company disclosed related-party loans and short-term borrowings, loaned funds to affiliates (BioFirst) and a warrant exercise arrangement with Lind to raise equity proceeds. The business continues multiple clinical programs (ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, ABV-1703) and milestone-based license payments tied to IND, Phase II, Phase III and NDA events.
ABVC BioPharma, Inc. reported continued operating losses and negative working capital while advancing multiple clinical programs and relying on financing and related-party support. For the six months ended June 30, 2025 the company recorded a net loss of $2.332 million versus a loss of $1.047 million in the prior period. Basic and diluted net loss per share for the quarter/period presented include $(0.13) and
ABVC BioPharma reported continued operating losses and negative working capital as of June 30, 2025. Revenue was nil while operating expenses rose to $2.29 million for the quarter, producing a net loss of $2.33 million for the quarter and $3.28 million for the six months ended June 30, 2025. Cash flows from operations were negative while financing activities provided $2.54 million, partially offsetting investing outflows of $0.67 million. Current liabilities totaled $6.53 million producing a working capital deficit of $3.76 million. The company holds long-term investments of $2.84 million and prepayments for investments and asset acquisitions totaling about $1.82 million. Clinical-stage assets include multiple drugs and a medical device in Phase I/II or Phase II, with milestones and licensing payments outlined for IND, Phase II, Phase III and NDA events.